"""
Question: 1101 

Evidence: This study focuses on the development and validation of an HIV-1 subtype C specific genotypic drug resistance assay for use in South African patients failing HAART. Overall, we have developed and validated a more affordable “in-house” drug resistance assay designed specifically for HIV-1 subtype C that can be used to effectively monitor patients failing ARV therapy.

Rationale: The paper describes developing and validating a new in-house assay and presents original sequencing results and performance comparisons, indicating previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Viral RNA from the 90 patients and 10 VQA plasma samples was extracted, amplified and sequenced using the ViroSeq HIV-1 Genotyping System Version 2.0. Two hundred and sixty of the 295 (88%) samples were successfully amplified and sequenced using the “in-house” method.

Rationale: The methods and results explicitly state that HIV samples were amplified and sequenced.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing (viral load >1000 RNA copies/ml) and were used to validate the “in-house” drug resistance assay. Lastly, 295 recently infected patient samples from seven African sites … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: All described samples are patient-derived plasma or external quality assurance panel samples; there is no description of in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Drug resistance testing can be performed using either phenotypic or genotypic assays. Optimal extraction and PCR amplification protocols for the “in-house” drug resistance assay were developed.

Rationale: The study focuses on genotypic sequencing and does not perform or report any phenotypic susceptibility testing or in vitro IC measurements.

Answer: No
"""

"""
Question: 2101 

Evidence: The fasta sequences created from ViroSeq were submitted to the Stanford Database (http://hivdb.stanford.edu/index.html) to generate an HIV-1 drug resistance report. The “in-house” sequence data were submitted to the Stanford Database to generate an HIV-1 drug resistance report and to determine subtype, as described previously.

Rationale: The paper reports submission to the Stanford HIVDB, not to GenBank, and provides no GenBank accession numbers.

Answer: No
"""

"""
Question: 2102 

Evidence: The fasta sequences created from ViroSeq were submitted to the Stanford Database (http://hivdb.stanford.edu/index.html) to generate an HIV-1 drug resistance report. The “in-house” sequence data were submitted to the Stanford Database to generate an HIV-1 drug resistance report and to determine subtype, as described previously.

Rationale: No GenBank accession numbers are reported for any isolates, lab or otherwise.

Answer: No
"""

"""
Question: 2103 

Evidence: The fasta sequences created from ViroSeq were submitted to the Stanford Database (http://hivdb.stanford.edu/index.html) to generate an HIV-1 drug resistance report. The “in-house” sequence data were submitted to the Stanford Database to generate an HIV-1 drug resistance report and to determine subtype, as described previously.

Rationale: The paper provides no GenBank accession numbers; therefore specific accession numbers cannot be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: Seventy-six of the 81 samples were found to have identical mutation profiles generated by the two HIV-1 drug resistance assays. Of the five that were different all had additional mutations that were present in mixtures, indicating the presence of minority quasispecies harboring drug resistance mutations.

Rationale: The paper discusses mutation profiles in aggregate and concordance between assays but does not list per-sample mutation lists.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV-1 subtype C is the predominant subtype circulating in the heterosexual population in South Africa, and worldwide. Overall, we have developed and validated a more affordable “in-house” drug resistance assay designed specifically for HIV-1 subtype C.

Rationale: The study explicitly concerns HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Subtype analysis revealed that the subtype distribution was 53% subtype C (n = 138), 29% subtype A1 (n = 76), 9% subtype D (n = 23), 1% subtype B (n = 3) and 8% were unassigned (n = 20). The 10 samples had viral loads ranging from 3557 to 57,005 copies/ml, and were of known subtype (four subtype B, three subtype C, one subtype A1, one subtype A2 and one subtype F) and resistance profiles.

Rationale: The paper provides subtype distributions across the sequenced cohorts and panel samples.

Answer: Subtypes C, A1, D, B, A2, F, and unassigned (recombinant) forms
"""

"""
Question: 2303 

Evidence: Most genotyping methods detect HIV drug resistance by sequencing the protease (PR) and reverse transcriptase (RT) regions of the pol gene. The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced on one 96 well plate.

Rationale: The targeted gene regions are explicitly described.

Answer: Protease (PR) and reverse transcriptase (RT) regions of pol
"""

"""
Question: 2304 

Evidence: Most genotyping methods detect HIV drug resistance by sequencing the protease (PR) and reverse transcriptase (RT) regions of the pol gene. The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced on one 96 well plate.

Rationale: These statements confirm that pol (PR and RT) sequences were obtained.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing (viral load >1000 RNA copies/ml) and were used to validate the “in-house” drug resistance assay. Two hundred and ninety-five recently infected patient samples from seven African sites in Kilifi and Kangemi in Kenya, Kigali in Rwanda, Cape Town in South Africa, Masaka and Entebbe in Uganda and Lusaka and Copperbelt in Zambia, were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: The locations of sample collection are explicitly listed.

Answer: South Africa; Kenya (Kilifi, Kangemi); Rwanda (Kigali); Uganda (Masaka, Entebbe); Zambia (Lusaka, Copperbelt)
"""

"""
Question: 2402 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing (viral load >1000 RNA copies/ml) and were used to validate the “in-house” drug resistance assay. Two hundred and ninety-five recently infected patient samples from seven African sites … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: The paper describes the cohorts and sites but does not provide collection years for the sequenced samples.

Answer: NA
"""

"""
Question: 2502 

Evidence: Samples were diluted according to their concentration and dideoxy (chain termination) sequencing performed … using the ABI PRISM BigDye Terminator version 3.1 cycle sequencing kit. Sequence data were obtained using an ABI 3100 genetic analyzer.

Rationale: Dideoxy chain-termination with BigDye on an ABI 3100 indicates Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Samples were diluted according to their concentration and dideoxy (chain termination) sequencing performed … using the ABI PRISM BigDye Terminator version 3.1 cycle sequencing kit. Sequence data were obtained using an ABI 3100 genetic analyzer.

Rationale: The methods describe Sanger sequencing; no NGS technology is mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: Samples were diluted according to their concentration and dideoxy (chain termination) sequencing performed … 13 μl of PCR product … Sequence data were obtained using an ABI 3100 genetic analyzer. Generally, population-based genotyping assays are favored since they identify both novel and known mutations.

Rationale: Direct sequencing of PCR products in a population-based genotyping assay indicates no cloning prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Generally, population-based genotyping assays are favored since they identify both novel and known mutations. Samples were diluted … and dideoxy (chain termination) sequencing performed … of PCR product.

Rationale: Population-based sequencing implies bulk PCR product sequencing rather than single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Samples were diluted … and dideoxy (chain termination) sequencing performed … of PCR product. Sequence data were obtained using an ABI 3100 genetic analyzer.

Rationale: The workflow describes direct sequencing of PCR products with no molecular cloning steps.

Answer: No
"""

"""
Question: 2601 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing (viral load >1000 RNA copies/ml). Viral RNA from the 90 patients and 10 VQA plasma samples was extracted, amplified and sequenced.

Rationale: The sequencing was explicitly performed on plasma-derived viral RNA.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing (viral load >1000 RNA copies/ml). Viral RNA from the 90 patients and 10 VQA plasma samples was extracted, amplified and sequenced.

Rationale: Only plasma samples are described; there is no mention of PBMC-derived sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Of the 100 patient samples sequenced with the “in house” drug resistance assay, 14 did not have complete bidirectional sequencing data. Two hundred and sixty of the 295 (88%) samples were successfully amplified and sequenced using the “in-house” method.

Rationale: The paper reports 100 sequenced in the validation set and 260 sequenced from the multi-site cohort, totaling 360 plasma samples sequenced.

Answer: 360
"""

"""
Question: 2604 

Evidence: Ninety plasma samples were obtained … and were used to validate the “in-house” drug resistance assay. Viral RNA from the 90 patients and 10 VQA plasma samples was extracted, amplified and sequenced.

Rationale: The study consistently references plasma; no PBMC sequencing is reported, so the number is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: Ninety plasma samples were obtained … (viral load >1000 RNA copies/ml) and were used to validate the “in-house” drug resistance assay. The 10 samples had viral loads ranging from 3557 to 57,005 copies/ml.

Rationale: Reported viral loads indicate active viremia at the time of sampling.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Viral RNA from the 90 patients and 10 VQA plasma samples was extracted, amplified and sequenced. Viral RNA was extracted from all the 395 plasma samples using the automated Roche MagNa Pure LC analyzer.

Rationale: Sequencing was performed on plasma viral RNA, not on proviral DNA.

Answer: No
"""

"""
Question: 2701 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: The paper does not specify ages or indicate that samples were from infants/children.

Answer: NA
"""

"""
Question: 2702 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples from seven African sites … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: The paper describes routine testing and observational sampling; it does not specify clinical trial participation.

Answer: NA
"""

"""
Question: 2703 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: There is no statement that all individuals were in a clinical trial.

Answer: NA
"""

"""
Question: 3101 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing … and were used to validate the “in-house” drug resistance assay. Two hundred and ninety-five recently infected patient samples from seven African sites … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: The study includes 90 patient samples plus 295 recently infected patient samples (excluding the 10 VQA panels), totaling 385 individuals.

Answer: 385
"""

"""
Question: 3102 

Evidence: Two hundred and sixty of the 295 (88%) samples were successfully amplified and sequenced using the “in-house” method. Of the 100 patient samples sequenced with the “in house” drug resistance assay, 14 did not have complete bidirectional sequencing data.

Rationale: Not all individuals in the 295-sample cohort were sequenced successfully, indicating that not all individuals in the paper underwent sequencing.

Answer: No
"""

"""
Question: 4101 

Evidence: Two hundred and ninety-five recently infected patient samples from seven African sites … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay. Overall, we have developed and validated a more affordable “in-house” drug resistance assay designed specifically for HIV-1 subtype C...

Rationale: Although “recently infected” implies likely ART-naive, the paper never explicitly states ART-naive status for these individuals.

Answer: NA
"""

"""
Question: 4102 

Evidence: This study focuses on the development and validation of an HIV-1 subtype C specific genotypic drug resistance assay for use in South African patients failing HAART. Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing (viral load >1000 RNA copies/ml) and were used to validate the “in-house” drug resistance assay.

Rationale: The validation set consists of patients described in the context of failing HAART and routine resistance testing, which typically involves ARV-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay. This study focuses on … use in South African patients failing HAART.

Rationale: The paper does not explicitly state that any cohort was ART-naive; thus it cannot be confirmed that both ART-naive and ART-experienced sequences were reported.

Answer: NA
"""

"""
Question: 4104 

Evidence: Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay. Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing …

Rationale: The paper does not specify ART status for the recently infected cohort; it therefore does not provide a count of ART-naive samples.

Answer: NA
"""

"""
Question: 4105 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing … and were used to validate the “in-house” drug resistance assay. Overall, we have developed and validated a more affordable “in-house” drug resistance assay … Future work should focus on improving the performance of this assay in non HIV-1 subtype C samples.

Rationale: The paper does not provide detailed ART regimen histories or complete treatment histories for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay. Overall, results demonstrate the “in-house” approach used in this study amplifies successfully more HIV-1 subtype C samples than ViroSeq…

Rationale: The recently infected cohort was used to assess assay performance across subtypes, not to estimate transmitted drug resistance prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay. Overall, results demonstrate the “in-house” approach used in this study amplifies successfully more HIV-1 subtype C samples than ViroSeq…

Rationale: The paper does not report pretreatment drug resistance prevalence metrics.

Answer: No
"""

"""
Question: 4301 

Evidence: Furthermore, the drug resistance profiles generated for these nine patient samples indicated that 78% (n = 7) had mutations that would result in resistance to both nucleoside and non-nucleoside reverse transcriptase inhibitors. Most genotyping methods detect HIV drug resistance by sequencing the protease (PR) and reverse transcriptase (RT) regions of the pol gene.

Rationale: The only drug classes specifically mentioned in relation to observed resistance are NRTIs and NNRTIs.

Answer: NRTIs and NNRTIs
"""

"""
Question: 4302 

Evidence: The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced. Overall, we have developed and validated a more affordable “in-house” drug resistance assay …

Rationale: The study did not include integrase sequencing or report on integrase inhibitor use.

Answer: No
"""

"""
Question: 4303 

Evidence: Furthermore, the drug resistance profiles … indicated that 78% (n = 7) had mutations that would result in resistance to both nucleoside and non-nucleoside reverse transcriptase inhibitors. Most genotyping methods detect HIV drug resistance by sequencing the protease (PR) and reverse transcriptase (RT) regions of the pol gene.

Rationale: The paper does not report information about individuals receiving protease inhibitors; it only notes NRTI/NNRTI resistance in a subset.

Answer: No
"""

"""
Question: 4304 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing … and were used to validate the “in-house” drug resistance assay. Two hundred and ninety-five recently infected patient samples … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: The paper provides no regimen details and does not state whether all individuals received the same ART.

Answer: NA
"""

"""
Question: 4305 

Evidence: The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced. Overall, we have developed and validated a more affordable “in-house” drug resistance assay …

Rationale: Integrase was not sequenced and there is no report of integrase inhibitor use; INSTI status is not specified.

Answer: NA
"""

"""
Question: 4403 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing … Two hundred and ninety-five recently infected patient samples … were used …

Rationale: The paper does not report the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4404 

Evidence: Ninety plasma samples were obtained … for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used …

Rationale: No data are provided on how many individuals received more than two regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: Ninety plasma samples were obtained … for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used …

Rationale: The study does not report regimen counts per individual, so it cannot be determined whether all received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: Ninety plasma samples were obtained … for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used …

Rationale: Regimen numbers are not reported; it cannot be concluded that all individuals received only one regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: Ninety plasma samples were obtained … for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used …

Rationale: The paper does not mention specific drugs such as dolutegravir.

Answer: NA
"""

"""
Question: 4502 

Evidence: Ninety plasma samples were obtained … for routine HIV-1 drug resistance testing. Two hundred and ninety-five recently infected patient samples … were used …

Rationale: The paper does not mention specific drugs such as darunavir.

Answer: NA
"""

"""
Question: 5101 

Evidence: Seventy-six of the 81 samples were found to have identical mutation profiles generated by the two HIV-1 drug resistance assays. Furthermore, the drug resistance profiles … indicated that 78% (n = 7) had mutations that would result in resistance to both nucleoside and non-nucleoside reverse transcriptase inhibitors.

Rationale: The paper gives limited subset information and does not provide a comprehensive count of individuals with any resistance mutation across all sequenced samples.

Answer: NA
"""

"""
Question: 5102 

Evidence: The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced. Most genotyping methods detect HIV drug resistance by sequencing the protease (PR) and reverse transcriptase (RT) regions of the pol gene.

Rationale: Integrase was not sequenced; therefore no INSTI-resistance mutations were reported or could be found.

Answer: 0
"""

"""
Question: 5103 

Evidence: Furthermore, the drug resistance profiles … indicated that 78% (n = 7) had mutations that would result in resistance to both nucleoside and non-nucleoside reverse transcriptase inhibitors. Overall, results demonstrate the “in-house” approach …

Rationale: The paper does not specify specific NRTIs such as TDF or report counts of TDF-associated resistance.

Answer: NA
"""

"""
Question: 5104 

Evidence: The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced. Most genotyping methods detect HIV drug resistance by sequencing the protease (PR) and reverse transcriptase (RT) regions of the pol gene.

Rationale: Integrase was not assessed; thus no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Drug resistance testing can be performed using either phenotypic or genotypic assays. Optimal extraction and PCR amplification protocols for the “in-house” drug resistance assay were developed.

Rationale: The study performed genotypic sequencing, not phenotypic susceptibility testing; therefore no phenotypic method was used.

Answer: NA
"""

"""
Question: 6102 

Evidence: Samples were diluted … and dideoxy (chain termination) sequencing performed … Sequence data were obtained using an ABI 3100 genetic analyzer.

Rationale: No phenotypic assays or IC metrics (IC50/IC90) are reported.

Answer: No
"""

"""
Question: 6103 

Evidence: Samples were diluted … and dideoxy (chain termination) sequencing performed … Sequence data were obtained using an ABI 3100 genetic analyzer.

Rationale: The paper contains no phenotypic susceptibility results or fold-change data.

Answer: No
"""

"""
Question: 6104 

Evidence: Drug resistance testing can be performed using either phenotypic or genotypic assays. Optimal extraction and PCR amplification protocols for the “in-house” drug resistance assay were developed.

Rationale: Only genotypic assays were performed, so no phenotypic assay was used.

Answer: NA
"""

"""
Question: 6105 

Evidence: Overall, results demonstrate the “in-house” approach … The use of only 5 primers to generate a fully bidirectional sequence with coverage of PR 1-99 and RT 1-240 increases the number of samples that can be sequenced …

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: Drug resistance testing can be performed using either phenotypic or genotypic assays. Optimal extraction and PCR amplification protocols for the “in-house” drug resistance assay were developed.

Rationale: No phenotypic susceptibility testing was performed; hence no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing … and were used to validate the “in-house” drug resistance assay. The 10 samples … were of known subtype … and resistance profiles.

Rationale: The study used clinical and panel-derived viral RNA; there is no mention of engineered site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: Ninety plasma samples were obtained from patients samples sent for routine HIV-1 drug resistance testing … Lastly, 295 recently infected patient samples from seven African sites … were used to determine the impact of HIV-1 subtype on the “in-house” drug resistance assay.

Rationale: All sequences were from patient-derived samples or external panels; no in vitro passage experiments are described.

Answer: No
"""